Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Ophthalmology Market Research

Cell Therapy And Gene Therapy Markets

Best Price Guarantee Length Publisher Published Date SKU
from $5,000 291 Pages Kalorama Information February, 2022 KLI17152120

Attention: There is an updated edition available for this report.
Best Price Guarantee
Price from $5,000
Length 291 Pages
Publisher Kalorama Information
Published Date February, 2022
SKU KLI17152120

Cell Therapy And Gene Therapy Markets

Cell and Gene Therapy World Market and Market Potential 22-021

Authoritative Information on Cell and Gene Therapy Markets

Cell and Gene Therapy World Market and Market Potential from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

  • Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
Scope

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:
  • Dermatology, including:
  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cardiovascular and Blood Disorders, including:
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • Oncology, including:
  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Ophthalmic Conditions, including:
  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)
  • Musculoskeletal Conditions and Disorders, including:
  • Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Other Conditions, including:
  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)


  • Executive Summary
    • Overview
    • Scope and Methodology
    • Market Overview and Potential
  • Introduction to Cell and Gene Therapy
    • Introduction
      • Cell Therapy
        • Table Adult vs. Embryonic Stem Cells
      • Gene Therapy
        • Table Somatic vs. Germ Line Gene Therapy
      • Viral Vector System and New Developments
        • Table Selected Examples of Viruses in Gene Therapy
      • Non-viral Systems for Transporting Genes
      • Gene Editing
    • Cell and Gene Therapy: Characteristics
      • Table Cell Therapy vs Gene Therapy
    • Staffing
    • Manufacturing Process for CAR-T
      • Leukapheresis
      • Activation
      • Transduction
      • Expansion
    • Cell and Gene Therapy Manufacturing Processes
      • Table Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and
      • Table Selected Recent Viral Vector Company Expansion
    • Cost
    • Reimbursement
    • Logistics
    • Mergers and Acquisitions
      • Table Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
    • Partnerships, Agreements and Collaborations
      • Table Selected Company Partnerships, Agreements and Collaborations in the Cell and Gene Therapy
    • Financing and Funding Deals
      • Table Recent Cell and Gene Therapy Recent Financing Deals
    • Regulatory Developments
      • Fast Track
      • Orphan Drug
      • Breakthrough Therapy
      • Accelerated Approval
      • Priority Review
        • Table Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
      • Individualized Gene Therapy Approval Process
    • Development and Pipeline Overview
    • Development Progress
    • Development by Condition/Disorder
    • Global Participation in Cell and Gene Therapy Development
    • Phase III Development
      • Table Phase III Development Cell and Gene Therapies, Select Projects
    • End User
      • Hospitals
      • Research Institutes
      • Wound Care Centers
      • Cancer Centers
  • Cell and Gene Therapy Markets in Dermatology
    • Overview
      • Table Wound Prevalence by Type
    • Market Outlook
    • Principal Products
      • Adipocel
      • Apligraf
      • CureSkin
      • Dermagraft
      • Epicel
      • Grafix
      • Holoderm
      • Kaloderm
      • KeraHeal/KeraHeal-Allo
      • LaViv
      • Orcel
      • Quencell
      • RECELL
      • Rosmir
      • Stempeutics/Cutisera
      • StrataGraft
      • Stravix
      • TransCyte
        • Table Cell and Gene Therapy in Dermatological Diseases and Disorders
    • Trends in Research and Development
      • Table Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
      • Table Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data
      • Phase III Development
        • Table Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022
    • Market Breakdown of Cell and Gene Therapies
      • Table Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
      • Dermatology Cell and Gene Therapy Market by Indication
        • Table Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)
    • Regional Market Summary
      • Table Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
    • Competitor Summary
      • Table Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
    • Overview
      • Cardiovascular Disease
      • Selected Blood Disorders
    • Market Outlook
    • Principal Products
      • Collategene
      • Hearticellgram
      • HeartSheet
      • Leqvio
      • Neovasculgen
      • Stempeucel
      • Zynteglo
      • Cord Blood Products
        • Table Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
    • Trends in Research and Development
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data
      • Phase III Development
        • Table Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through January 2022
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022
    • Market Breakdown of Cell and Gene Therapies
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
      • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
    • Regional Market Summary
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Markets in Oncology
    • Overview
      • Biochemistry of Cancer Cells
    • Causes of Cancer Growth
      • Environmental Factors, DNA, RNA
        • Table Virus Association with Human Cancer
      • Cellular Oncogenes
      • Tumor Suppressor Genes
    • Global Cancer Burden
    • Market Outlook
    • Principal Products
      • Abecma
      • APCeden
      • Breyanzi
      • CreaVax-RCC
      • Gendicine
      • Imlygic
      • Immuncell-LC
      • Kymriah
      • Provenge
      • Tecartus
      • Yescarta
        • Table Cell and Gene Therapy in Oncology
    • Trends in Research and Development
      • Table Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
      • Table Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
      • Phase III Development
        • Table Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
    • Market Breakdown of Cell and Gene Therapies
      • Table Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
      • Oncology Cell and Gene Therapy Market by Cancer Type
        • Table Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
    • Regional Market Summary
      • Table Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
    • Competitor Summary
      • Table Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cell and Gene Therapy Markets in Ophthalmic Conditions
    • Overview
    • Market Outlook
    • Principal Products
      • Holoclar
      • Luxturna
        • Table Cell and Gene Therapy in Ophthalmic Conditions
    • Trends in Research and Development
      • Table Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
      • Table Ophthalmology Cell and Gene Therapies in Development by Method, January 2022 Data
      • Phase III Development
        • Table Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022
    • Market Breakdown of Cell and Gene Therapies
      • Table Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
    • Regional Market Summary
      • Table Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
    • Overview
    • Market Outlook
    • Principal Products
      • AlloStem
      • BIO4
      • Carticel
      • Cartiform
      • CartiLife
      • Cartistem
      • Chondron
      • JACC
      • MACI
      • Ortho-ACI and Ortho-ATI
      • Ossron
      • Osteocel and Osteoplus
      • Spherox
      • Trinity Elite and Trinity Evolution
        • Table Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
    • Trends in Research and Development
      • Table Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
      • Table Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022 Data
      • Phase III Development
        • Table Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022
    • Market Breakdown of Cell and Gene Therapies
      • Table Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
      • Musculoskeletal Cell and Gene Therapy Market by Indication
        • Table Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
    • Regional Market Summary
      • Table Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
    • Competitor Summary
      • Table Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cell and Gene Therapy Markets in Neurological-Related Disorders
    • Overview
    • Market Outlook
    • Principal Products
      • Libmeldy
      • NeuroNata-R
      • Onpattro
      • SKYSONA
      • Stemirac
      • Zolgensma
        • Table Cell and Gene Therapy in Neurological Diseases and Disorders
    • Trends in Research and Development
      • Phase III Development
        • Table Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022
      • Orphan Drug, Fast Track, Breakthrough Designations
        • Table Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022
    • Market Breakdown of Cell and Gene Therapies
      • Table Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
    • Regional Market Summary
      • Table Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
    • Competitor Summary
      • Table Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cell and Gene Therapy Markets in Other Conditions
    • Overview
    • Market Outlook
    • Principal Products
      • Alofisel
      • Cupistem
      • Givlaari
      • Glybera
      • Oxlumo
      • Rethymic
      • Ryplazim
      • Strimvelis
      • Temcell/Prochymal/Ryoncil
        • Table Cell and Gene Therapy in Other Diseases and Disorders
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
      • Table Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
    • Regional Market Summary
      • Table Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
    • Competitor Summary
  • Cell and Gene Therapy Market Review
    • Market Influences
      • Global Demographics
        • Table Global Population, through 2050 (population in millions)
      • Cost Containment
        • Table Cost Comparisons for Selected Commercialized Cell and Gene Therapies
    • Cell and Gene Therapy and Viral Vector Shortages
    • Global Market Summary
      • Table Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
    • Cell vs. Gene Therapy Markets
      • Table Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
    • Regional Market Overview
      • Table Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)
    • United States
      • Table Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions)
      • Table Major Cell and Gene Therapy Product Approvals, FDA
    • Europe/European Union
      • Table Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
      • Table Major Cell and Gene Therapy Approvals by EMA
    • Other Countries
      • Table Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
      • Table Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
    • Competitor Ranking in Cell and Gene Therapy Markets
      • Table Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
  • Market Participants
    • Leading Influencers
    • Advaxis, Inc. (Biosight Therapeutics)
      • Table Advaxis Corporate Summary
      • Company Summary
      • Products
    • AlloSource
      • Table AlloSource Corporate Summary
      • Company Summary
      • Products
    • Alnylam Pharmaceuticals, Inc.
      • Table Alnylam Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Amgen
      • Table Amgen Corporate Summary
      • Company Summary
      • Products
    • AnGes Inc.
      • Table AnGes Corporate Summary
      • Company Summary
      • Products
    • Anterogen Co Ltd.
      • Table Anterogen Corporate Summary
      • Company Summary
      • Products
    • Atara Biotherapeutics
      • Table Atara Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • Athersys, Inc
      • Table Athersys Corporate Summary
      • Company Summary
      • Products
    • BioCardia
      • Table BioCardia Summary
      • Company Summary
      • Products
    • Biogen, Inc.
      • Table Biogen Corporate Summary
      • Company Summary
      • Products
    • BioMarin Pharmaceuticals
      • Table BioMarin Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • bluebird bio, Inc.
      • Table bluebird bio Corporate Summary
      • Company Summary
      • Products
    • BrainStorm Cell Therapeutics
      • Table BrainStorm Cell Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb Corporate Summary
      • Company Summary
      • Products
    • Caladrius Biosciences
      • Table Caladrius Biosciences Corporate Summary
      • Company Summary
      • Products
    • Candel Therapeutics
      • Table Candel Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Castle Creek Biosciences
      • Table Castle Creek Corporate Summary
      • Company Summary
      • Products
    • Celyad Oncology
      • Table Celyad Oncology Corporate Summary
      • Company Summary
      • Products
    • Cook Myosite, Inc
      • Table Cook Myosite Corporate Summary
      • Company Summary
      • Products
    • Cytori Therapeutics, Inc
      • Table Cytori Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Dendreon Pharmaceuticals LLC
      • Table Dendreon Corporate Summary
      • Company Summary
      • Products
    • FerGene, Inc/Ferring Pharmaceuticals
      • Table FerGene Corporate Summary
      • Company Summary
      • Products
    • Gamida Cell Ltd.
      • Table Gamida Cell Corporate Summary
      • Company Summary
      • Products
    • GenSight Biologics S.A.
      • Table GenSight Biologics Corporate Summary
      • Company Summary
      • Products
    • Gilead Sciences, Inc.
      • Table Gilead Sciences Corporate Summary
      • Company Summary
      • Products
    • Gradalis, Inc
      • Table Gradalis Corporate Summary
      • Company Summary
      • Products
    • Helixmith
      • Table Helixmith Corporate Summary
      • Company Summary
      • Products
    • Inovio Pharmaceuticals, Inc.
      • Table Inovio Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Kiadis Pharma B.V. (Sanofi)
      • Table Kiadis Pharma Corporate Summary
      • Company Summary
      • Products
    • Medeor Therapeutics
      • Table Medeor Therapeutics Corporate Summary
      • Company Summary
      • Products
    • MEDIPOST Co, Ltd.
      • Table MEDIPOST Corporate Summary
      • Company Summary
      • Products
    • MeiraGTx
      • Table MeiraGTxCorporate Summary
      • Company Summary
      • Products
    • Merck & Co., Inc.
      • Table Merck & Co. Corporate Summary
      • Company Summary
      • Products
    • Mesoblast Ltd.
      • Table Mesoblast Corporate Summary
      • Company Summary
      • Products
    • Neurotech Pharmaceuticals. Inc.
      • Table Neurotech Corporate Summary
      • Company Summary
      • Products
    • Northwest Biotherapeutics, Inc.
      • Table Northwest Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • Novartis AG
      • Table Novartis Corporate Summary
      • Company Summary
      • Products
    • NuVasive Biologics
      • Table NuVasive Biologics Corporate Summary
      • Company Summary
      • Products
    • Orchard Therapeutics
      • Table Orchard Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Organogenesis
      • Table Organogenesis Corporate Summary
      • Company Summary
      • Products
    • Orthofix
      • Table Orthofix Corporate Summary
      • Company Summary
      • Products
    • Osiris Therapeutics, Inc.( part of Smith & Nephew)
      • Table Osiris Corporate Summary
      • Company Summary
      • Products
    • Pharmicell
      • Table Pharmicell Corporate Summary
      • Company Summary
      • Products
    • Pluristem Therapeutics, Inc.
      • Table Pluristem Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sangamo Therapeutics
      • Table Sangamo Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sanofi
      • Table Sanofi Corporate Summary
      • Company Summary
      • Products
    • Sotio a.s.
      • Table Sotio Corporate Summary
      • Company Summary
      • Products
    • Spark Therapeutics
      • Table Spark Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Tessa Therapeutics, Ltd.
      • Table Tessa Therapeutics Corporate Summary
      • Company Summary
      • Products
    • uniQure N.V.
      • Table UniQure Corporate Summary
      • Company Summary
      • Products
    • VBL Therapeutics (Vascular Biogenics Ltd.)
      • Table VBL Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Vericel Corporation
      • Table Vericel Corporate Summary
      • Company Summary
      • Products

$5,000
$7,500
$10,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings